Showing results (111-120 of 170) with videos related to
Sort By:
Pageof 17
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.Blood|September 10, 2005
Dysfunctional T regulatory cells in multiple myelomaRao H Prabhala, Paola Neri, Jooeun E Bae, et al.Cancer Research|December 18, 2003
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.Blood|November 20, 2008
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingMarc S Raab, Iris Breitkreutz, Giovanni Tonon, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
Novel therapies in the treatment of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.Blood|March 25, 2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, et al.Blood|June 21, 2003
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaLaurence Catley, Ellen Weisberg, Yu-Tzu Tai, et al.British Journal of Haematology|July 19, 2006
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomibReshma Shringarpure, Laurence Catley, Deepak Bhole, et al.The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.Pageof 17